Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs Luci

Coivas
Graded #197

Lower grade

vs+4.799999999999997
Luci
Graded #101

Higher grade

The verdict

Luci takes it — 71/100 to 66.2/100.

Luci grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luci is a budget-focused GLP-1 telehealth platform offering compounded medications with upfront pricing: compounded semaglutide as low as $99/month and compounded tirzepatide as low as $145/month, plus oral…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLuci +14
70
84
Dose & formulationLuci +11
64
75
Clinical oversightCoivas +13
84
71
Labs & monitoringCoivas +1
54
53
FulfillmentCoivas +8
78
70
Contract termsLuci +35
20
55
Coivas · left barLuci · right bar

The numbers

MetricCoivasLuci
WeighScore66.2/10071/100
GradeCC
Scorecard rank#197#101
Semaglutide$149/mo (quarterly plan, compounded)$99/mo (starting dose, promotional rate, compounded)
Tirzepatide$229/mo (quarterly plan, compounded)$145/mo (starting dose, promotional rate, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Coivas

Graded #197 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
Luci

Graded #101 · C

Strengths

  • Budget-friendly compounded GLP-1 pricing (compounded semaglutide as low as $99/month, tirzepatide as low as $145/month)
  • Multiple formats: compounded semaglutide and tirzepatide injections plus oral semaglutide and tirzepatide pill kits
  • Upfront pricing with no insurance required and a fast 3-minute questionnaire to start
  • Care delivered through DrTelx, an independent US telehealth medical group, with ongoing support and dose optimization
  • HIPAA-compliant platform with a large self-reported member base (50,000+)

Where it loses points

  • Compounded medications are not FDA-approved for weight loss (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Available only in select U.S. states, and the full state list is not published
  • The compounding pharmacy partner is not named
  • Headline prices are 'as low as' rates (asterisked) — your actual monthly cost may be higher
  • No LegitScript certification displayed; marketing leans heavily on testimonials

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard